Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Pituitary TumorPituitary AdenomaPituitary Macroadenoma
Interventions
DRUG

Bevacizumab-IRDye800CW

Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery

DEVICE

Molecular Fluorescence Endoscopy platform

A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW | Biotech Hunter | Biotech Hunter